When McKesson Corp. faced legal exposure over opioids, Covington & Burling didn’t just get a big win for the pharmaceutical distributor—it won three times.

In a groundbreaking victory, partner Paul Schmidt won a 2022 bench verdict in the first bellwether trial to target distributors of opioids. U.S. District Senior Judge David Faber of the Southern District of West Virginia found McKesson and two other pharmaceutical distributors had sufficient programs in place to monitor suspicious prescription orders.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]